Bobbie Baby

Bobbie Baby

Laura Modi and Sarah Hardy launched Bobbie in 2018 in San Francisco, designing the product to meet stricter European nutritional standards long preferred by parents who had been importing formula via gray-market channels. The founding thesis was simple: the US regulatory restructuring after the 2022 Abbott plant shutdown would reward a brand that had already built European-style sourcing and transparent manufacturing. Bobbie was operational and growing before the crisis hit, turning a niche parental preference into a mainstream demand signal. Bobbie operates as a direct-to-consumer subscription business layered on a single-product formula SKU, a structure that keeps inventory turns predictable and churn measurable. The company sources its base formula from an FDA-registered facility in Vermont, with a secondary manufacturing partnership in Ohio that came online in 2023 to support the national shortage response. Its funded R&D pipeline includes a USDA-certified organic whole-milk toddler formula, a direct counter to the legacy brands' "gentle" and "sensitive" line extensions that dominate grocery shelves. Venture backers have included Park West, VMG Partners, and over 100 angel investors, many of whom were parents in the Bobbie subscriber base. The company raised a $70 million Series C in early 2023 led by PowerPlant Partners, following a $50 million Series B the prior year. October 2022: Bobbie acquired a 50,000-square-foot manufacturing facility in Heath, Ohio — a former Abbott distribution center — committing to bring formula production in-house for the first time. This pivot from contract manufacturing to vertical integration is the firm's structural differentiator, giving it control over batch-level quality in a category where trust is the only real competitive moat. Bobbie has also built a proprietary "Bobbie Labs" product testing protocol and participates in the FDA's Nutrition Innovation Strategy, unusual for an early-stage consumer packaged goods company. Structurally, Bobbie is a venture-backed consumer company with an FDA compliance burden that makes it an odd hybrid — not a family office, not a traditional fund, and not purely a marketing-driven DTC brand. Its most unusual feature is the regulatory-first sourcing model, which means FDA enforcement actions against competitors function as an asymmetric growth lever. The founding team's policy fluency, not just its brand aesthetic, explains why Bobbie became the default recommendation of pediatricians during the 2022–2023 formula crisis.